Prospective validation of a prognostic score to improve patient selection for oncology phase I trials.
about
Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancersA Case-Control Study Brings to Light the Causes of Screen Failures in Phase 1 Cancer Clinical TrialsBRAF mutations in advanced cancers: clinical characteristics and outcomesRisk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experienceAntiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancerMegestrol acetate versus metronomic cyclophosphamide in patients having exhausted all effective therapies under standard careRandomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial.The role of palliative chemotherapy in hospitalized patients.Early mortality and overall survival in oncology phase I trial participants: can we improve patient selection?A retrospective analysis of clinical outcome of patients with chemo-refractory metastatic breast cancer treated in a single institution phase I unitBody composition, symptoms, and survival in advanced cancer patients referred to a phase I serviceSurvival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experienceTemporal evolution of patient characteristics enrolled on phase I trials.Perceptions and referral trends into phase I oncology trials: results of a clinical surveyThe neutrophil-lymphocyte ratio and its utilisation for the management of cancer patients in early clinical trials.Higher Risk of Infections with PI3K-AKT-mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials.Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic.Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies.Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin.Predictors of early treatment discontinuation in patients enrolled on Phase I oncology trials.Development and validation of an ultra-deep next-generation sequencing assay for testing of plasma cell-free DNA from patients with advanced cancer.Phase I trial outcomes in older patients with advanced solid tumoursTargeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trialsIncreased pretreatment levels of serum LDH and ALP as poor prognostic factors for nasopharyngeal carcinoma.Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies.The prognostic significance of left ventricular ejection fraction in patients with advanced cancer treated in phase I clinical trials.The role of age on dose-limiting toxicities in phase I dose-escalation trials.Nomogram to predict cycle-one serious drug-related toxicity in phase I oncology trials.Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experienceTumor growth rate is an early indicator of antitumor drug activity in phase I clinical trialsValidation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trialsEarly oncology clinical trial design in the era of molecular-targeted agents.Designs and challenges for personalized medicine studies in oncology: focus on the SHIVA trial.Risks and benefits of phase 1 clinical trial participation.Multiplex KRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction.Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies.Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials.Analysis of esophagogastric cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase 1 trials.Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer.
P2860
Q28484970-36E38D68-2EC5-49D5-A371-2FD6F9662FCAQ28551817-1E9A1675-F649-4F97-A2B8-27261CBF3FA0Q28743591-D0ED8D3A-EFF7-4009-92B7-AA91E4F6908AQ33399986-0EC68B19-62FD-4F8D-8469-AAF3B3C4316BQ33779691-40D44D55-B0E5-4A0E-B4C3-DAE21D4B51A7Q33794896-116F311E-F3D5-42E2-85D0-7023048014B5Q33877385-484C657D-06C2-48B9-828D-9B84E5CFEB42Q33982668-C2994FB6-6F7E-498E-A62A-82FE7B579A01Q34040965-BEE8572B-2209-4278-AAC5-1D72C5CAC2EAQ34122784-BE5068EB-EB8C-4899-8526-97081F1CC45DQ34123648-8B4F3EA1-D4D1-406A-9B67-2D0F3C0B02DAQ34252383-B08DA153-8C6B-4D6D-A1C9-9A9E5AA3B300Q34352316-0E08EC52-9924-485E-8066-2953C1D290B1Q35104935-982CED5D-033D-494A-9433-EBF148F25873Q35274955-E889F2D4-C6AD-4874-9DE8-5E1970DF5BB7Q35462692-B3E4F46F-F76E-4915-AB91-D2F65E3B9952Q35584482-FB679904-1597-4478-9480-9C7CAD3EBC9CQ35828697-046CEDEB-558B-424D-93BF-CD77A371EED6Q36288003-60274688-48D1-4E5D-B045-3522AF7F6660Q36326389-6D93F95F-DD1B-46E3-AC70-CE0F098169A1Q36378903-FF8513D7-3C52-4111-9606-AD5C0A1C151DQ36547934-3EC6EFBE-2569-48F0-9C0A-DF3BFDAC82B4Q36984860-94227A63-B1FA-44A9-9EA0-7A6C17799825Q37183651-A83E0FC2-A14A-4CC3-892F-BB5F1B95B734Q37222606-75873016-A1C8-4940-8DE4-D2A9E78E9C17Q37342909-C0E3F6E5-D47E-42F1-90D3-49FC1BAE861AQ37494348-0AC03D34-0B13-4111-94D2-521BEBF7ABDDQ37552648-2BBB0F1F-0AA8-40B3-8709-81DF56D58D3AQ37570408-7B8B2110-4069-4CED-9609-04F4D9A41A11Q37577932-4BBD3BFA-D42B-4ABE-A0A1-1D9118ADE363Q37626194-1765DD6F-B7DA-4DB6-800D-B79161022BA2Q37665702-597FC79A-CAD4-4529-8845-2455AB256AA6Q37783623-1D6CE38E-E338-48CD-9804-6EA89F4F0E09Q38060583-ABD3A3BA-7163-43E0-8552-3BFD549609D6Q38222465-B7662679-3318-4BE4-8B67-FD131A25A301Q38376723-9A3CA5EC-749E-4ECE-9C90-EAEDEB46CC0AQ38636711-BCACB8DD-241F-4472-9543-93FC243BAF56Q38735014-A11DF584-7D05-42BE-80CB-DEF3EFF13C82Q38924049-F18B2B99-3C73-4504-8E60-80662947E2BAQ39442254-59B0F5B6-1EDF-4265-ACF5-46F68FE8CE8D
P2860
Prospective validation of a prognostic score to improve patient selection for oncology phase I trials.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Prospective validation of a pr ...... n for oncology phase I trials.
@en
Prospective validation of a pr ...... n for oncology phase I trials.
@nl
type
label
Prospective validation of a pr ...... n for oncology phase I trials.
@en
Prospective validation of a pr ...... n for oncology phase I trials.
@nl
prefLabel
Prospective validation of a pr ...... n for oncology phase I trials.
@en
Prospective validation of a pr ...... n for oncology phase I trials.
@nl
P2093
P356
P1476
Prospective validation of a pr ...... n for oncology phase I trials.
@en
P2093
David Olmos
Hendrik-Tobias Arkenau
Ian Judson
Johann de Bono
Joo Ern Ang
Jorge Barriuso
P304
P356
10.1200/JCO.2008.19.5081
P407
P577
2009-03-30T00:00:00Z